Apyx medical corporation reports third quarter 2023 financial results and updates full year 2023 financial outlook

Clearwater, fla.--(business wire)--apyx medical corporation (nasdaq:apyx) (the “company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as renuvion®, today reported financial results for its third quarter ended september 30, 2023, and updated its financial expectations for the full year ending december 31, 2023. third quarter 2023 financial summary: total revenue of $12.0 million, up 31% year-over-year. advanced energy revenue of $9.8 million,.
APYX Ratings Summary
APYX Quant Ranking